

A small-molecule tyrosine kinase inhibitor elicits a novel anti-influenza function via an EGFR-independent, GBF1-dependent pathway

<sup>1</sup>Xu Zhou, <sup>1</sup>Lingxiang Zhu, <sup>1</sup>Cheryl Bondy, <sup>1</sup>Jun Wang, <sup>2</sup>Qianwen Luo and <sup>1</sup>Yin Chen\*

<sup>1</sup>Department of Pharmacology and Toxicology, School of Pharmacy, University of Arizona, Tucson, AZ.

<sup>2</sup>Department of Biosystems Engineering, University of Arizona, Tucson, AZ.

\* Corresponding author: ychen@pharmacy.arizona.edu; Tel: 520-626-4715; Fax: 520-626-2466


### **Supplemental Materials and Methods:**

Minigenome assay (1)


Cells were transfected with pCDNA constructs for influenza A/WSN/33 virus PB1, PB2, and PA (100 ng each) and NP (200 ng), the RNA polymerase II-driven Renilla luciferase reporter pRL-SV40 (Promega) (250 ng), and the influenza virus-specific RNA polymerase I driven firefly luciferase reporter (vRNALuc) (250 ng). The transfection was performed with TransIT-293(Mirus) in OptiMEM (Invitrogen). Twenty-four hours after incubation, cells were harvested, and firefly luciferase and Renilla luciferase expression were determined using the Dual Luciferase Assay Kit (Promega).

### **Reference:**


52. Hoffmann H.H, Kunz A., Simon V.A., Palese P., Shaw M.L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. *Proc Natl Acad Sci USA* **2011**, *108*, 5777-5782, doi: 10.1073/pnas.1101143108



**Figure S1.** AG1478 repressed IAV production. Beas2b cells were infected with A/WSN/33 viruses at MOI=0.1. Cells were treated with  $2\mu\text{M}$  AG1478 daily (direct dosing without media change). Media were collected at 24, 48 and 72 hours after infection and used for the plaque assay. Data shown are virus titer/ml,  $n=4$ , #:  $p < 0.05$ .



**Figure S2.** AG1478 did not affect IAV mRNA transcription, protein expression and viral polymerase activity. Beas2b cells were treated with AG1478 and infected with A/WSN/1933. A) IAV NP and B) PA gene expression were measured using real-time PCR. IAV NP forward primer: 5'-AGACTGATGGAGAACGCCAGA-3', reverse primer 5'-TCGGTGCACATTTGGATGTAG-3'; IAV PA forward primer 5'-TCG TTC AGGCTCTTAGGGACA-3', Reverse primer 5'-AAGCAAACCCAGGGATCATT-3'. C) IAV M1, NP, PA, HA, NA protein expression were measured using western blot analysis. ACTIN was used as a loading control. D) Minigenome assay was used to evaluate the effect of AG1478 on viral polymerase activity.



**Figure. S3.** Viral protein expression in the presence of AG1478. Beas2b cells were treated with 2 $\mu$ M AG1478 and infected with A/WSN/1933 for 24 hours. Total proteins, which were later used for IP analysis in Figure 6A, were analyzed for GBF1, NP, M1, PA, HA and M2. ACTIN was used as a loading control.